ReviewCells2024
A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives.
Review in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Locoregional delivery of CAR T cells in high-grade gliomas: a systematic analysis of safety, efficacy, and emerging biomarkers of response.Journal for immunotherapy of cancer · 2026Pooled it
- T cell immunity in glioma and potential implications for immunotherapy: A systematic review.Neuro-oncology · 2026Pooled it
- Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma.Cancer research · 2026Article
- Focused ultrasound for enhancing cell-based immunotherapies in neuro-oncology.Neuro-oncology advances · 2026Review
- Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.Current treatment options in oncology · 2026Review
- Multimodal profiling of CAR T cells against glioblastoma using a microengineered 3D tumor-on-a-chip model.Bioactive materials · 2026Article
- Isocitrate Dehydrogenase-Mutant Astrocytomas: Risk Stratification and Therapeutic Advance.MedComm · 2026Review
- The safety and efficacy of bispecific T-cell engagers (TCEs) in patients with glioma.Clinical and experimental medicine · 2026Review
- The dynamic myeloid-enriched microenvironment of glioblastoma: a major challenge to immunotherapy efficacy.Frontiers in immunology · 2026Review
- Directed evolution of chlorotoxin enhances MMP-2 recognition and improves CAR-T-cell activity in glioblastoma modelsFrontiers in bioengineering and biotechnology · 2026Article
- Antibody therapies in glioblastoma: Overcoming micro-environmental barriers.Iranian journal of basic medical sciences · 2026Review
- CAR-T Cell Therapy in Glioblastoma: Overcoming Immunological Barriers and Advancing Clinical Translation.Cancer management and research · 2026Review
- CAR-T Cell Therapy for Central Nervous System Tumors.Methods in molecular biology (Clifton, N.J.) · 2026Review
- Physiologically based pharmacokinetic model for CAR-T cell delivery and efficacy in solid tumors.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- CAR-T cells immunotherapy in the treatment of glioblastoma.Cancer immunology, immunotherapy : CII · 2025Review
- Management of persistent residual growth of high-grade glioma: a case report highlighting clinical and therapeutic challenges.Oxford medical case reports · 2025Article
- Beyond borders: engineering organ-targeted immunotherapies to overcome site-specific barriers in cancer.Drug delivery and translational research · 2025Review
- Global research trends in CAR-T cell therapy for glioblastoma: a bibliometric and visualized analysis.Discover oncology · 2025Article
- Physiologically-based pharmacokinetic model for CAR-T cells delivery and efficacy in solid tumors.bioRxiv : the preprint server for biology · 2025Article
- Glioblastoma: From Pathophysiology to Novel Therapeutic Approaches.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Glioblastoma (GBM) is the most common primary malignant brain tumor, with a median overall survival of less than 2 years and a nearly 100% mortality rate under standard therapy that consists of surgery followed by combined radiochemotherapy. Therefore, new therapeutic strategies are urgently needed. The success of chimeric antigen receptor (CAR) T cells in hematological cancers has prompted preclinical and clinical investigations into CAR-T-cell treatment for GBM. However, recent trials have not demonstrated any major success. Here, we delineate existing challenges impeding the effectiveness of CAR-T-cell therapy for GBM, encompassing the cold (immunosuppressive) microenvironment, tumor heterogeneity, T-cell exhaustion, local and systemic immunosuppression, and the immune privilege inherent to the central nervous system (CNS) parenchyma. Additionally, we deliberate on the progress made in developing next-generation CAR-T cells and novel innovative approaches, such as low-intensity pulsed focused ultrasound, aimed at surmounting current roadblocks in GBM CAR-T-cell therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.